Platelet activating factor and ischemia

Abstract

Recently, the deleterious influence of leucocytes in hemorheological disturbances and thrombotic processes has been described. The Platelet-activating factor (PAF) is produced by leucocytes and is also a potent stimulating factor of these cells. It can also activate the endothelial cells and the platelets but in the limited area of its production. A better understanding of its mechanism of action (cell receptors, regulating systems) is necessary to conceive new pharmacological approaches in vascular diseases. PAF antagonists are numerous: some molecules, synthetic or derived from plants extracts, are structural analogues. Other molecules compete with PAF receptors on cells. We review the main mechanisms of actions of PAF and their consequences in vascular disorders. Pharmacological modulations are also described. Clinical trials could be set up on this basis.